Published Studies Related to Trusopt (Dorzolamide Ophthalmic)
[Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. [2011.06]
CONCLUSION: MK-0507A has a significantly superior IOP-lowering effect relative to timolol. MK-0507A also showed a non-inferior IOP-lowering effect relative to the concomitant therapy. MK-0507A was safe compared to both timolol and concomitant therapy.
[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol]. [2011.05]
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol... CONCLUSIONS: Both fixed combinations were similarly effective in reducing intraocular pressure and ocular pulse amplitude. Adverse effects related to both treatments were mild and well-tolerated, though itching occurred most frequently in the eyes treated with dorzolamide/timolol. Copyright (c) 2011 Sociedad Espanola de Oftalmologia. Published by Elsevier Espana. All rights reserved.
Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers. 
CONCLUSION: Both formulations showed comparable results obtained at a time probably equal to the maximum effect concerning the primary target parameter lowering of IOP 2 h post dose. The safety profile of both preparations showed no difference.
[Double-masked, phase III comparative study of the combination ophthalmic
solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in
patients with glaucoma and ocular hypertension]. [Article in Japanese] 
CONCLUSION: MK-0507A has a significantly superior IOP-lowering effect relative to
Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. [2010.12]
BACKGROUND: The aim of this study was to compare the efficacy and tolerability of preservative-free (PF) and preservative-containing (PC) formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure (IOP)... CONCLUSIONS: In patients with elevated IOP, PF and PC dorzolamide/timolol were equivalent in efficacy for change in trough and peak IOP, and had generally similar tolerability.
Clinical Trials Related to Trusopt (Dorzolamide Ophthalmic)
Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs [Completed]
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and
brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy
(bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
MK0507A Phase III Double-Blind, Comparative Study [Completed]
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1. 0% / timolol 0. 5%)
with 1) timolol 0. 5% and with 2) concomitant therapy with dorzolamide 1. 0% / timolol 0. 5% in
patients with glaucoma and ocular hypertension.
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension [Not yet recruiting]
This study will investigate the safety and efficacy of Triple Combination Therapy with
dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with
glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol
maleate combination therapy.
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost [Completed]
24-Hour IOP Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-Angle Glaucoma [Completed]
The primary objective of this crossover trial is to compare the 3-month mean 24-hour
intraocular pressure (IOP) control and safety of dorzolamide/timolol fixed combination (DTFC)
given twice daily, versus latanoprost/timolol fixed combination (LTFC) given in the evening
and placebo given in the morning, versus adjunctive therapy with DTFC given twice daily and
latanoprost 0. 005% given once in the evening in open-angle glaucoma patients who are
insufficiently controlled with latanoprost monotherapy.
Reports of Suspected Trusopt (Dorzolamide Ophthalmic) Side Effects
Eyelid Oedema (7),
Intraocular Pressure Increased (6),
Reading Disorder (5),
Poor Quality Drug Administered (5),
Eyelid Irritation (5), more >>